In an unusual move, the U.S. Department of Health and Human Services (“HHS”), rather than the U.S. Food and Drug Administration (“FDA”), announced the availability of an interim enforcement policy in the Federal Register on October 30, 2026 (91 Fed. Reg. 68,526), addressing compounding with six peptide bulk drug substances. The policy provides limited... READ MORE
HHS, Not FDA, Takes the Lead on Peptide Compounding
Posted on November 4, 2026 in Health Law News
Published by: Hall Render